NIPH Clinical Trials Search

JRCT ID: jRCTs031200400

Registered date:05/03/2021

Effects of olfactory stimulation by L-menthol on dyspnea on exertion in chronic lung disease: A pilot study

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedChronic obstructive pulmonary disease, Idiopathic interstitial pneumonias
Date of first enrollment14/04/2021
Target sample size34
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Aroma seals coated with L-menthol are applied to a surgical mask and the mask is worn for a walking test.


Primary Outcomemodified Borg Scale before and after 6-minute walking test
Secondary OutcomeSpO2 (before and after 6MWT) Pulse rate (before and after 6MWT) 6 minute walking distance St. George`s Respiratory Questionnaire (SGRQ) Steps/day Nagasaki University Respiratory ADL Questionnaire (NRADL) Quadriceps force Grip force Respiratory muscle force (PImax/PEmax) pulmonary function Dyspnea Language Questionnaire Multidimensional Dyspnea Profile Adverse event

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
Include criteria1) Patients with COPD or IIPs who are attending a respiratory medicine in our hosuital 2) Patients who are 20 years of age or older at the time of obtaining consent 3) Patients who are able to walk independently 4) Patients who can accurately perform respiratory function tests and 6MWT 5) Patients whose condition is stable and who have not changed their treatment for more than three months 6) Patients who have been fully informed of the contents of this study and have given written consent 7) Patients who are in or have completed an outpatient rehabilitation program, have stable symptoms, and are not scheduled for an outpatient rehabilitation program during this study
Exclude criteria1) Patients with severe orthopedic or central nervous system disease who need assistance with daily living 2) Patients who have been hospitalized for an exacerbation of an primary disease within the past six months 3) Patients with unstable cardiac disease 4) Patients with a history of other serious lung diseases such as occupational lung, sarcoidosis, airway hypersensitivity, malignant diseases, or lung infections caused by immunodeficiency 5) Patients with nasal obstruction and olfactory disturbances 6) Patients who are judged by the principal investigator/assistant physician to have a risk of compromising patient safety or to have difficulty complying with the protocol

Related Information


Public contact
Name Takeshi Inagaki
Address 1-8-1 Inohana Chuo-ku, Chiba-shi Chiba Japan 260-8677
Telephone +81-43-222-7171
Affiliation Chiba University Hospital
Scientific contact
Name Seiichiro Sakao
Address 1-8-1 Inohana Chuo-ku, Chiba-shi Chiba Japan 260-8677
Telephone +81-43-222-7171
Affiliation Chiba University Hospital